Faruqi and Faruqui, LLP Logo
Share this page

Hi-Tech Pharmacal Co., Inc. (HITK)

(NasdaqGS: HITK)


Faruqi & Faruqi, LLP, Partner Juan E. Monteverde Launches an Investigation of Hi-Tech Pharmacal Co., Inc. Over the Proposed Sale of the Company to Akorn, Inc.

Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Hi-Tech Pharmacal Co., Inc. (“Hi-Tech” or the “Company”) (NasdaqGS: HITK) for potential breaches of fiduciary duties in connection with their conduct related to the sale of the Company to Akorn, Inc. (NasdaqGS: AKRX) in a deal valued at $640 million.  Under the terms of the proposed transaction, Hi-Tech’s stockholders will receive $43.50 in cash for each share of Hi-Tech common stock they own.  However, Hi-Tech has reached $44.30 in its 52-week high.

The investigation focuses on whether Hi-Tech’s Board of Directors breached their fiduciary duties to the Company’s stockholders by failing to conduct an adequate and fair sales process prior to agreeing to this proposed transaction, whether and by how much this proposed transaction undervalues the Company to the detriment of Hi-Tech’s shareholders.

If you own common stock in Hi-Tech and wish to obtain additional information and protect your investments free of charge, please contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@faruqilaw.com or by telephone at (877) 247-4292 or (212) 983-9330.


Request Information

Please tell us about yourself by completing the form below and we will provide you with additional
information at no cost to you on how to join the Class Action.

  • Company:
    Hi-Tech Pharmacal Co., Inc. (HITK)

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

MergerInfo Request
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 08/28/2013

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.